Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Ovarian Cancer|Breast Cancer|Pancreatic Cancer|Prostate Cancer|Additional Indications Below for Module 4 and 5|Non-small Cell Lung Cancer|Colorectal Cancer|Bladder Cancer|Gastric Cancer|Biliary Cancer|Cervical Cancer|Endometrial Cancer|Small Cell Lung Cancer Only in Module 5
Interventions: DRUG: AZD5305|DRUG: Paclitaxel|DRUG: Carboplatin|DRUG: T- Dxd|DRUG: Dato-DXd|DRUG: Camizestrant
Sponsor: AstraZeneca